- Jazz zeroes in on next-gen T cell engagers with AbCellera dealThe potentially $4 billion collaboration is the latest example of drugmakers working to broaden the use of T cell engagers, which, so far, have had limited success outside of certain blood cancers.BioPharma Dive · 1mo ago↗ source
- STAT+: FDA appears open to Moderna’s flu vaccine ahead of adcommUniQure will submit Huntington's therapy for approval, Eli Lilly buys 4E Therapeutics, and more biotech newsSTAT · 1mo ago↗ source
- STAT+: Pharmalittle: We’re reading about hackers extorting Novo, an FDA about-face, and moreA cyber extortion group claimed to have stolen more than a terabyte of data from Novo Nordisk and said it is exploring selling some of the dataSTAT · 1mo ago